Provider review
CareBareRX Review: It Cites a Real Trial and Misprices Four of Its Own Products
CareBareRX does two things no other company in this review wave does. It publishes four dispensing pharmacies with full street addresses, phone numbers and websites, plus four prescribing clinicians with NPI numbers you can check in the federal registry. And on its weight-loss page it links an actual clinical trial — PubMed 33567185, the STEP 1 study — and quotes it correctly, down to the 14.9% versus 2.4% placebo comparison over 68 weeks. It is the only company in this wave to cite a trial on a product page at all — one other links PubMed from a blog post, and the remaining eight cite nothing anywhere. Against that: four separate "Starting at" prices rendered on its own pages are contradicted by its own catalogue, including an NAD+ product advertised from $199 when the only NAD+ product it sells costs $325. Its medical consent asks patients to agree in advance that they "will not dispute the payments with my credit card company". And the rebill interval is never published — the product record says four weekly injections, every page says per month, and those are not the same year.
Compounded only
Phase 3 trials
Named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens www.carebarerx.com. A link is not a recommendation to take anything.
Provenance
What CareBareRX actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded semaglutide — $199 at the 0.25 mg starting dose. ⚠ That is the STARTING dose, and CareBareRX publishes the whole ladder: ".25mg- $199 / .5mg- $249 / 1mg- $249 / 1.5mg- $299 / 2mg- $299". Semaglutide is designed to be titrated, so a maintenance patient pays $299 — half again as much. The rebill interval is not published: the product record says "4 Weekly Subcutaneous Injections" while every page says "/mo". If it bills every 28 days the year is $2,587 rather than $2,388.
- Compounded tirzepatide — $299 at 2.5 mg and 5 mg, from CareBareRX's own published ladder: "2.5mg- $299 / 5mg- $299 / 7.5mg- $349 / 10mg- $349 / 12.5mg-$399 / 15mg- $399". Same unpublished rebill interval as semaglutide. ⚠ The multi-month bundles carry empty descriptions — no dose, no supply length, no cancellation terms — and the three-month bundle works out dearer per month than the one-month price, so no per-month rate can honestly be derived from them.
- NAD+ Therapy — $325 in CareBareRX's own catalogue — the only NAD+ product it sells. ⛔ Its own page advertises "NAD+ Treatments Starting at $199", a price that exists nowhere in the catalogue. The $325 figure is the one filed.
- Sermorelin acetate — ⚠ Not filed. CareBareRX's prices are rendered client-side and no sermorelin figure was reproducible in a static fetch on 2026-08-10. Its state-supply note warns that for patients in eleven states "cost may vary" because a secondary pharmacy fills the order.
Evidence
Is there a human trial at all?
One row per product, graded on how far the published human evidence goes for the use it is sold for — not for the molecule in general. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
2
Products with a human trial
Out of 4 reviewed here.
2
Registry records cited
Each read live from ClinicalTrials.gov, never from memory.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from CareBareRX’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Compounded semaglutideSemaglutide · Compounded (503A)Claim matches the trials
“After 68 weeks of weekly semaglutide treatment, participants experienced an average body weight reduction of 15%. The semaglutide group saw a 14.9% decrease from baseline, compared to just 2.4% in the placebo group. (Source) […] From 233 CareGLP participants reported an average weight loss of 8.6 lbs in the first month on CareBareRX semaglutide.”
Phase 3 trials
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Tested the approved 2.4 mg product over 68 weeks. No compounded semaglutide from any seller has been through a registered trial.
This is the best-evidenced claim in the entire review wave and it deserves to be said plainly. CareBareRX links the actual paper — PubMed 33567185 — under a heading reading "SOURCES", and every figure it quotes is correct: 68 weeks, 14.9% from baseline in the treatment arm, 2.4% in the placebo arm. It does not round the placebo away, it does not say "clinical studies show", and it does not attribute the result to its own product. No other company in this wave attaches a citation to a product claim; one links PubMed from a blog post, and eight cite nothing anywhere. ⚠ Two reservations. STEP 1 tested the approved finished product, and what CareBareRX dispenses is a compounded preparation that has never been in a registered trial — a distinction the page does not draw. And the second sentence is a different kind of claim entirely: "233 CareGLP participants reported an average weight loss of 8.6 lbs in the first month" is uncontrolled self-reported data from a related brand's customers, presented in the same block as a randomised trial.1
Compounded tirzepatideTirzepatide · Compounded (503A)Claim matches the trials
“Weight Loss Treatments. […] Prescription medication only available if prescribed after an online consultation with a healthcare provider. Physicians may prescribe compounded medications as needed to meet patient needs.”
Phase 3 trials
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. Tested the approved product at the highest tolerated dose over 72 weeks.
CareBareRX makes no efficacy claim specific to tirzepatide — its cited evidence block is about semaglutide — so there is nothing here that outruns the trials. It does publish the full dose ladder rather than a single headline figure, which is a genuine courtesy for a drug that is titrated over months. The standing caveat applies unstated: SURMOUNT-1 tested the approved product, not a compounded preparation.2
NAD+ TherapyNAD+ (nicotinamide adenine dinucleotide) · Compounded (503A)No trial supports this claim
“Boost Energy. Support Healthy Aging. Live Fully. CareBareRX NAD⁺ therapy supports your body at the cellular level — for energy, focus, and vitality you can feel. […] NAD⁺ (Nicotinamide Adenine Dinucleotide) is a vital coenzyme found in every cell, essential for energy production, mitochondrial health, and cellular repair. As we age, NAD⁺ levels naturally decline, impacting how we feel and function. CareBareRX NAD⁺ therapy is designed to help maintain healthy energy metabolism, promote cognitive performance, and support overall vitality.”
No human trial
As of 10 August 2026, a ClinicalTrials.gov v2 intervention search for injected NAD+ in humans returns no completed randomised trial supporting a restoration-of-function claim, and a PubMed search for "nicotinamide adenine dinucleotide" combined with injection or subcutaneous, filtered to the randomised-controlled-trial publication type, returns zero records. No registered study of injected NAD+ reports a cognitive endpoint. The substantial human literature concerns ORAL precursors — nicotinamide riboside and nicotinamide mononucleotide — which are different molecules by a different route.
The description of the molecule is accurate — NAD+ is a coenzyme, it is central to energy production, and levels do decline with age — and CareBareRX correctly calls it a coenzyme where a competitor in this wave calls it a peptide. The claims stacked on top have no completed human trial behind them: "vitality you can feel", "promote cognitive performance", "support overall vitality". No registered study of injected NAD+ reports a cognitive endpoint at all. ⚠ Note the contrast with this company's own semaglutide page, which links a real trial and quotes it correctly. CareBareRX plainly knows how to attach a claim to evidence; it does it for the molecule that has evidence and not for the one that does not. The page also carries the phrase "Science-Backed Treatments" in a scrolling banner, with no science attached to this product.3
Sermorelin acetateSermorelin · Compounded (503A)No trial supports this claim
“Medications may include: SERMORELIN ACETATE. […] Patients in those states will be supplied by secondary pharmacies. Cost may vary.”
No human trial
As of 10 August 2026, a ClinicalTrials.gov v2 search returns NO interventional record naming sermorelin as the intervention, in any phase and at any status. Six query forms were run — intervention "sermorelin", "sermorelin acetate", "GHRH(1-29)", "GHRH 1-29", "growth hormone releasing hormone 1-29" and "Geref", its withdrawn brand name — plus a free-text search of every field. The 27 studies returned are all different molecules: tesamorelin (TH9507/Egrifta), GHRH(1-44), or unspecified diagnostic "GHRH". In PubMed, "sermorelin" appears in 24 titles or abstracts and ZERO carry the randomised-controlled-trial or clinical-trial publication type. The searches discriminate: in the same pass tirzepatide returned 158 registry records and 126 trial papers, tesamorelin 17 and 21, bremelanotide 10 and 11.
CareBareRX sells sermorelin acetate and publishes no description of it — no mechanism, no indication, no benefit, no contraindication. The molecule surfaces in the catalogue and in a state-supply note explaining that patients in eleven states "will be supplied by secondary pharmacies. Cost may vary." There is therefore no efficacy claim to hold against the literature, and no trial to hold it against either: no registered study names sermorelin as an intervention under any of six query forms. Graded on the sale rather than on a sentence, because there is no sentence.4,5
Dispensing chain
Who actually fills your prescription
- Belmar Pharmacy — 6597 N 92nd St, Suite 105, Scottsdale, AZ 85260
- Strive Pharmacy — 21143 Hawthorne Blvd, Suite 305, Torrance, CA 90503
- Epiq Scripts — 625 Herndon Ave, Suite D, Clovis, CA 93612
- Casa Pharma Rx — 12855 Capricorn St, Stafford, TX 77477
Read the full account
Joint-best in the roster, and the only one that publishes STREET ADDRESSES. CareBareRX's FAQ lists four dispensing pharmacies in full — Belmar Pharmacy, 6597 N 92nd St Suite 105, Scottsdale AZ 85260, 800.525.9473, belmarpharmasolutions.com; Strive Pharmacy, 21143 Hawthorne Blvd Suite 305, Torrance CA 90503, 855.405.5993; Epiq Scripts, 625 Herndon Ave Suite D, Clovis CA 93612, 833.654.3553; and Casa Pharma Rx, 12855 Capricorn St, Stafford TX 77477, 877.937.6868 — each with a working website. It also names the telehealth platform with its own address (CareValidate, 4575 Webb Bridge Rd, Alpharetta GA 30005, 844.357.3601) and FOUR prescribing clinicians with NPI numbers: Dr. Ana Lisa Carr MD (1689841744), Dr. Kelly Tenbrink MD (1346482684), Dr. HirenKimar Italia MD (1487815387) and Dr. David Mansour DO (1689164949). A reader can verify every one of those in the federal NPPES registry. ⚠ Belmar's own FDA letter of 31 March 2023 was CLOSED OUT on 30 October 2023 and belongs to the pharmacy rather than to CareBareRX; it is recorded here and filed nowhere. ⚠ Carr and Tenbrink also prescribe for another company in this wave through the same Lion MD / CareValidate platform — a shared backend, which is NOT grounds to treat the brands as duplicates and does not diminish the disclosure. ⚠ What is still withheld is which of the four fills a given order, and CareBareRX's own state notes concede the answer changes: for eleven states, sermorelin and NAD+ patients "will be supplied by secondary pharmacies. Cost may vary."
Read on August 2026 from https://www.carebarerx.com/faq
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No certificate of analysis, lot number, potency result, sterility result, named laboratory or batch lookup is published for any product. The site's quality signal is a scrolling banner reading "HIPAA-Compliant · No Insurance Required · Science-Backed Treatments" — the first is a privacy standard, the second a payment model, and the third is the claim that would need evidence. ⚠ What CareBareRX publishes instead is arguably more useful than most testing language: the identity and street address of every pharmacy that might compound the medication, and the phone number of each. That does not tell a patient what was in their vial, but it tells them precisely who holds the record and how to ask. ⚠ It is also the only company in this wave to cite a study on a product page — PubMed 33567185 on its weight-loss page, quoted accurately — which makes the absence of any evidence on its NAD+ and sermorelin pages a choice rather than an incapacity.
Read on August 2026 from https://www.carebarerx.com/products/nad-therapy
Licensing
Licensed to dispense, and where
Coverage
Nationwide, with named no-ship states on specific non-GLP-1 products
Read the full licensing claim
CareBareRX does not publish a single coverage list; it publishes per-product restrictions, which is more granular than most and harder to read. Eleven states — Alabama, Arkansas, Alaska, Connecticut, Indiana, Kentucky, Louisiana, Michigan, Minnesota, Vermont and Wisconsin — are named as restricted for its two-in-one hair product and the tablet forms of tadalafil and sildenafil, with "No ship state: AL" attached to others. For NAD+ and sermorelin the note is different and worth quoting: patients in those states "will be supplied by secondary pharmacies. Cost may vary." No no-ship list is attached to the GLP-1 products at all, and no state is identified as excluded outright, so `statesExcluded` is empty because naming exclusions would mean inventing them. Clinical care is delivered through CareValidate by Lion MD, with four clinicians named and NPI-verifiable. ⚠ Payment terms are the weak point: the medical consent states that "All programs are auto-renewing and I consent to be automatically charged for any program I am a part of unless I explicitly request to cancel before my payment is processed. There are no refunds or exchanges. I certify that I am an authorized user of this credit card and that I will not dispute the payments with my credit card company." A consumer's right to dispute a card charge is not ordinarily a company's to collect in advance. A consult fee of $80 applies if no medication is prescribed.
Read on August 2026 from https://www.carebarerx.com/medical-consent
Regulatory
The FDA warning letter
Checked, and none found
Assessment
What holds up, and what does not
- It is the only company in this review wave that cites a clinical trial on a product page. Its weight-loss page cites PubMed 33567185 under a "SOURCES" heading and quotes STEP 1 accurately — 68 weeks, 14.9% versus 2.4% placebo.
- Four dispensing pharmacies published with full street addresses, phone numbers and websites — Belmar in Scottsdale, Strive in Torrance, Epiq Scripts in Clovis and Casa Pharma Rx in Stafford.
- Four prescribing clinicians named with NPI numbers, every one checkable in the federal NPPES registry.
Show 6 more
- The telehealth platform is named with its own corporate address and phone number rather than left as "our medical partner".
- It publishes the complete dose ladder for both GLP-1s rather than a single headline price, so a patient can see what titration will cost before starting.
- It correctly describes NAD+ as a coenzyme, where a competitor in this wave calls the same molecule a peptide that acts on the pituitary.
- The $80 consult fee that applies when no medication is prescribed is disclosed rather than discovered.
- Per-product state restrictions are published, including an explicit note that eleven states are supplied by secondary pharmacies for NAD+ and sermorelin.
- No FDA warning letter, screened against the live index on the full company name with a positive control that fired.
- Four "Starting at" prices rendered on its own pages are refuted by its own catalogue: $99 hair (cheapest is $180), $99 ED ($120), $199 NAD+ (the only NAD+ product is $325), and $749 Ozempic against $705.
- Its medical consent asks patients to agree that they "will not dispute the payments with my credit card company" — a chargeback right is not ordinarily a company's to collect in advance.
- "There are no refunds or exchanges", combined with programmes that are "auto-renewing" by default.
Show 9 more
- The rebill interval is never published. The product record says "4 Weekly Subcutaneous Injections" while every page says "/mo"; at 28 days the semaglutide year is $2,587 rather than $2,388.
- $199 is the 0.25 mg starting dose only. The published ladder reaches $299 for semaglutide and $399 for tirzepatide, and both drugs are designed to be titrated.
- The multi-month bundles have empty descriptions — no dose, no supply length, no cancellation terms — and the three-month bundle costs more per month than the one-month price.
- No certificate of analysis, lot number, potency or sterility result is published for any product.
- Its NAD+ page promises "vitality you can feel" and "cognitive performance" with no citation, on a site that demonstrably knows how to cite a trial when one exists.
- Sermorelin is sold with no published description at all — no mechanism, indication, benefit or contraindication — for a molecule with no interventional trial record under any name.
- "Science-Backed Treatments" scrolls across pages whose products have no science attached to them.
- Its own outcome claim — "233 CareGLP participants reported an average weight loss of 8.6 lbs in the first month" — is uncontrolled self-reported data from a related brand, presented in the same block as a randomised trial.
- Which of the four pharmacies fills a given order is not disclosed, and CareBareRX concedes the cost changes when a secondary pharmacy is used.
Verdict
The bottom line
CareBareRX is a company with an unusually good disclosure habit and an unusually careless storefront, and the two sit side by side on the same website. It publishes four pharmacies with street addresses, four clinicians with verifiable NPI numbers, and — alone in this wave of ten companies — an actual link to an actual clinical trial on the page selling the product, quoted correctly down to the placebo arm. Then four of its own advertised "Starting at" prices turn out not to exist in its own catalogue, including an NAD+ product offered from $199 when the only NAD+ it sells is $325. Its consent form asks you to promise not to dispute a card charge. And the interval it will charge you on is never stated: the product record says four weekly injections, every page says per month, and the difference is about $200 a year. If you are buying semaglutide, this is one of the better-documented places to do it — provided you read the dose ladder, because $199 is the starting dose and $299 is where titration lands. If you are buying NAD+ or sermorelin, note that the company which proved it can cite a trial has cited nothing at all for either.
Opens www.carebarerx.com. A link is not a recommendation to take anything.
The only company here that showed its working
Eight of the ten companies in this review wave cite no study anywhere at all — not a trial identifier, not a PubMed ID, not a link. A ninth, CoreAge Rx, links two PubMed records, but from blog posts and as general "see the literature" pointers, with no figure quoted and no product claim attached to them.
One company cites a trial on the page that is selling you the product.
CareBareRX's weight-loss page carries a block headed SOURCES:
"*After 68 weeks of weekly semaglutide treatment, participants experienced an average body weight reduction of 15%. The semaglutide group saw a 14.9% decrease from baseline, compared to just 2.4% in the placebo group. (Source)"
The link goes to PubMed 33567185 — the STEP 1 trial. 1
Every figure in that sentence is correct. Sixty-eight weeks is right. 14.9% from baseline in the treatment arm is right. And it reports the placebo arm — 2.4% — which is the number marketing copy usually drops, because keeping it makes the drug look less impressive and the claim look more honest.
It does not say "clinical studies show". It does not attribute STEP 1's result to its own compounded product. It names the study and links it.
Two things still need saying. STEP 1 tested the approved finished product; what CareBareRX dispenses is a compounded preparation that has never been in a registered trial, and the page does not draw that line. And immediately after the trial citation comes a second sentence of a completely different kind:
"*From 233 CareGLP participants reported an average weight loss of 8.6 lbs in the first month on CareBareRX semaglutide."
That is uncontrolled, self-reported data from a related brand's customers, sitting in the same block as a randomised controlled trial and formatted identically.
Full analysis — 6 more sectionsFour pharmacies, with the door numbers · Four prices that are not in the catalogue · What $199 actually buys · The sentence in the consent form · The two products with no evidence at all · What this means if you are buying
Four pharmacies, with the door numbers
The other thing CareBareRX does that almost nobody does. From its FAQ:
Belmar Pharmacy (Arizona) — 6597 N 92nd St, Suite 105, Scottsdale, AZ 85260 — 800.525.9473
Strive Pharmacy — 21143 Hawthorne Blvd, Suite 305, Torrance, CA 90503 — 855.405.5993
Epiq Scripts — 625 Herndon Ave, Suite D, Clovis, CA 93612 — 833.654.3553
Casa Pharma Rx — 12855 Capricorn St, Stafford, TX 77477 — 877.937.6868
Each with a working website. Most companies in this category will not tell you the name. This one gives you the street.
It goes further and names four prescribing clinicians with their NPI numbers — Dr. Ana Lisa Carr MD (1689841744), Dr. Kelly Tenbrink MD (1346482684), Dr. HirenKimar Italia MD (1487815387), Dr. David Mansour DO (1689164949) — every one verifiable in the federal NPPES registry. And it names the telehealth platform with its own address: CareValidate, 4575 Webb Bridge Rd, Alpharetta, GA 30005.
*(Belmar's own FDA warning letter of 31 March 2023 was closed out on 30 October 2023. It belongs to the pharmacy, not to CareBareRX, and it is recorded here rather than filed against this company. Carr and Tenbrink also prescribe for another brand in this wave through the same platform — a shared backend, which is not grounds to treat the companies as duplicates.)*
What is still withheld is which of the four will fill your order — and CareBareRX's own state notes concede that the answer changes what you pay: for eleven states, NAD+ and sermorelin patients "will be supplied by secondary pharmacies. Cost may vary."
Four prices that are not in the catalogue
Now the other half of the company.
| Advertised on the page | In its own catalogue | |---|---| | Hair treatments "Starting at $99" | cheapest is $180 | | ED treatments "Starting at $99" | cheapest is $120 | | NAD+ "Starting at $199" | the only NAD+ product is $325 | | Ozempic® "From $749/mo" | $705 in the catalogue and on /about |
Each of those is rendered on a live page, and each is contradicted by CareBareRX's own product data. The NAD+ one is the sharpest: it is not a starting dose or an introductory rate that later steps up — there is no $199 NAD+ product at all. The advertised figure is 39% below the only price that exists.
What $199 actually buys
The semaglutide headline is real, and it is the 0.25 mg starting dose. CareBareRX publishes the full ladder, which is genuinely more than most competitors do:
".25mg- $199 / .5mg- $249 / 1mg- $249 / 1.5mg- $299 / 2mg- $299"
And for tirzepatide:
"2.5mg- $299 / 5mg- $299 / 7.5mg- $349 / 10mg- $349 / 12.5mg-$399 / 15mg- $399"
Semaglutide is designed to be titrated upward over months. A patient who reaches a maintenance dose is paying $299, half again as much as the headline. Publishing the ladder is a courtesy; leading with the bottom rung is not.
Then there is the interval, which is never stated. The product record describes "4 Weekly Subcutaneous Injections" — a 28-day pack. Every page says "/mo". Those produce different years: twelve monthly charges is $2,388, thirteen 28-day charges is $2,587. CareBareRX does not say which one it does.
The multi-month bundles cannot be assessed at all. Their descriptions are empty — no dose, no supply length, no cancellation terms — and the three-month bundle works out dearer per month than paying monthly.
The sentence in the consent form
From the medical consent a patient signs:
"All programs are auto-renewing and I consent to be automatically charged for any program I am a part of unless I explicitly request to cancel before my payment is processed. There are no refunds or exchanges. I certify that I am an authorized user of this credit card and that I will not dispute the payments with my credit card company."
Auto-renewal disclosed up front is fine. "No refunds or exchanges" is harsh but common in this category.
The last clause is neither. A chargeback is a consumer protection that exists between a cardholder and their bank, and asking a patient to sign it away in advance — on the same form that authorises an auto-renewing charge, for a product whose rebill interval is not published — is the most consumer-unfriendly term found anywhere in this review wave.
The two products with no evidence at all
CareBareRX's NAD+ page reads: "Boost Energy. Support Healthy Aging. Live Fully… for energy, focus, and vitality you can feel… designed to help maintain healthy energy metabolism, promote cognitive performance, and support overall vitality."
The molecular description underneath it is accurate — NAD+ is a coenzyme, it is central to energy production, levels do decline with age, and CareBareRX correctly calls it a coenzyme where a competitor in this same wave calls it "a peptide that signals your own pituitary gland".
But injected NAD+ has no completed randomised human trial supporting a restoration-of-function claim, and no registered study of it reports a cognitive endpoint at all. 3 The human evidence for raising NAD+ concerns oral precursors — nicotinamide riboside and nicotinamide mononucleotide — different molecules by a different route.
Sermorelin gets less than that: CareBareRX sells sermorelin acetate and publishes no description of it whatsoever. No mechanism, no indication, no benefit, no contraindication. The molecule appears in the catalogue and in a state-supply footnote. And no registered trial names sermorelin as an intervention under any of six query forms, with no randomised-trial publication in PubMed either. 4 5
A scrolling banner on those pages reads "Science-Backed Treatments".
That is the frustrating thing about this company. It has demonstrated, on its semaglutide page, that it knows exactly how to attach a claim to a trial and quote it honestly. It does that for the one molecule with a large trial programme, and for the two with none it cites nothing.
What this means if you are buying
For semaglutide or tirzepatide, CareBareRX is among the better-documented options here: you can find out which pharmacies might fill it, ring them, look up the doctors, and read the whole dose ladder before you start. Budget for $299 rather than $199, and ask what the rebill interval actually is before you agree to anything, because the site does not say.
For NAD+, ignore the $199 on the page — the product costs $325 — and note that the company which proved it can cite a trial has cited nothing here.
For sermorelin, there is no description and no trial.
And read the consent form before you sign it.
Questions
Frequently asked questions
Does CareBareRX cite any real evidence?
Yes, and it is alone in this review wave in doing so on a product page. Its weight-loss page carries a block headed "SOURCES" linking PubMed 33567185 — the STEP 1 trial — and quotes it accurately: 68 weeks of weekly semaglutide, an average 15% body-weight reduction, 14.9% from baseline in the treatment arm against 2.4% in the placebo arm. Reporting the placebo arm is the part that matters, because that is the figure marketing copy usually drops. Two caveats. STEP 1 tested the approved finished product and CareBareRX dispenses a compounded preparation that has never been in a registered trial, which the page does not mention. And immediately after the citation sits a very different sort of claim — "233 CareGLP participants reported an average weight loss of 8.6 lbs in the first month" — which is uncontrolled self-reported data from a related brand, formatted identically to the trial result.
Why do CareBareRX's advertised prices not match its catalogue?
Four of them do not, and the company gives no explanation. Its pages advertise hair treatments "Starting at $99" when the cheapest is $180; ED treatments "Starting at $99" when the cheapest is $120; NAD+ "Starting at $199" when the only NAD+ product in the catalogue is $325; and Ozempic "From $749/mo" on an affiliate landing page against $705 in its own catalogue and on its /about page. The NAD+ one is the clearest, because it is not a starting dose that steps up later — no $199 NAD+ product exists at all, so the advertised figure sits 39% below the only real price. Where the two disagree, the catalogue figure is the one this review files.
Which pharmacy will fill my CareBareRX prescription?
One of four, and CareBareRX publishes all four with street addresses — the only company in this wave to do so. They are Belmar Pharmacy, 6597 N 92nd St Suite 105, Scottsdale AZ 85260 (800.525.9473); Strive Pharmacy, 21143 Hawthorne Blvd Suite 305, Torrance CA 90503 (855.405.5993); Epiq Scripts, 625 Herndon Ave Suite D, Clovis CA 93612 (833.654.3553); and Casa Pharma Rx, 12855 Capricorn St, Stafford TX 77477 (877.937.6868). It also names four prescribing clinicians with NPI numbers checkable in the federal NPPES registry, and the telehealth platform with its own address. What it does not tell you is which of the four gets your order — and its own notes concede that for eleven states, NAD+ and sermorelin patients "will be supplied by secondary pharmacies. Cost may vary."
What will CareBareRX actually charge me?
$199 buys the 0.25 mg starting dose of semaglutide, not the dose most patients end up on. CareBareRX publishes the whole ladder, which is to its credit: ".25mg- $199 / .5mg- $249 / 1mg- $249 / 1.5mg- $299 / 2mg- $299", and for tirzepatide "2.5mg- $299 / 5mg- $299 / 7.5mg- $349 / 10mg- $349 / 12.5mg-$399 / 15mg- $399". Since semaglutide is titrated upward over months, budget $299. The bigger unknown is the interval: the product record says "4 Weekly Subcutaneous Injections" — a 28-day pack — while every page says "/mo". Thirteen 28-day charges is $2,587 a year against $2,388 for twelve monthly ones, and CareBareRX never says which it does. A consult fee of $80 applies if no medication is prescribed, which is disclosed up front.
What is in CareBareRX's consent form?
One clause worth reading before you sign. The medical consent states: "All programs are auto-renewing and I consent to be automatically charged for any program I am a part of unless I explicitly request to cancel before my payment is processed. There are no refunds or exchanges. I certify that I am an authorized user of this credit card and that I will not dispute the payments with my credit card company." Auto-renewal disclosed in advance is reasonable and no-refund terms are common in this category. The final clause is neither: a chargeback is a protection that exists between a cardholder and their bank, and being asked to waive it in advance — on the same form authorising an auto-renewing charge whose interval is not published — is the most consumer-unfriendly term found in this review wave.
Is there evidence for CareBareRX's NAD+ or sermorelin?
For neither. Injected NAD+ has no completed randomised human trial supporting a restoration-of-function claim, and no registered study of it reports a cognitive endpoint — so "promote cognitive performance" and "vitality you can feel" have nothing behind them; the real human literature concerns oral precursors, which are different molecules by a different route. Sermorelin has less than that: a ClinicalTrials.gov search on 10 August 2026 returned no interventional record naming it as the intervention across six query forms, and PubMed holds no randomised-trial publication for it, against controls that returned 158, 17 and 10 registry records for molecules that do have trials. CareBareRX publishes no description of sermorelin at all — no mechanism, indication or contraindication. This is the same company that cites STEP 1 correctly on its semaglutide page, so the omission is a choice rather than an inability.
Glossary
Key terms
Show definitions
- STEP 1
- The phase 3 trial of once-weekly semaglutide 2.4 mg in 1,961 adults with overweight or obesity, published in 2021. It reported about 14.9% weight loss from baseline against 2.4% on placebo over 68 weeks. CareBareRX links it and quotes it correctly.
- Dose ladder
- The schedule of prices at each strength as a drug is titrated upward. GLP-1s are started low and increased over months, so the price at the lowest rung is rarely the price a patient settles at.
- Chargeback
- A cardholder's right to dispute a transaction with their bank. It exists between the customer and the card issuer. CareBareRX's consent asks patients to agree in advance that they will not exercise it.
- NPI
- A National Provider Identifier, listed in the federal NPPES registry and searchable by anyone. Published NPIs let a patient confirm that a named clinician exists and is who the site says they are. CareBareRX publishes four.
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off CareBareRX's own pages on the date stamped against it, and the URL it came from is published beside it.
Trials read from the registry
Phase, status and enrolment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 5 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine 387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
- US National Library of Medicine (2026). ClinicalTrials.gov v2 and PubMed searches for injected NAD+ in humans: no completed randomised trial supporting a restoration-of-function claim, no registered study reporting a cognitive endpoint, and zero randomised-controlled-trial publications for nicotinamide adenine dinucleotide combined with injection or subcutaneous administration. Run 2026-08-10.. ClinicalTrials.gov / PubMed. https://clinicaltrials.gov/search?intr=NAD%2B
- US National Library of Medicine (2026). ClinicalTrials.gov v2 search: no interventional record names sermorelin as the intervention. Six query forms run — "sermorelin", "sermorelin acetate", "GHRH(1-29)", "GHRH 1-29", "growth hormone releasing hormone 1-29", "Geref" — plus a free-text pass. Positive controls in the same pass: tirzepatide 158 records, tesamorelin 17, bremelanotide 10. Run 2026-08-10.. ClinicalTrials.gov. https://clinicaltrials.gov/search?intr=sermorelin
- US National Library of Medicine (2026). PubMed search: "sermorelin"[tiab] returns 24 records; "sermorelin"[tiab] AND randomized controlled trial[pt] returns 0, as does the clinical trial publication type. Positive controls: tirzepatide 126, tesamorelin 21, bremelanotide 11. Run 2026-08-10.. PubMed. https://pubmed.ncbi.nlm.nih.gov/?term=sermorelin%5Btiab%5D+AND+randomized+controlled+trial%5Bpt%5D
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.